Literature DB >> 11095808

Emerging Issues in Nosocomial Fungal Infections.

.   

Abstract

Nosocomial fungal infections remain a serious cause of morbidity and mortality. As immunodeficient populations increase, the incidence of nosocomial fungal infections continues to rise. Although a wide variety of new and emerging fungi can cause nosocomial infections, Candida species remain the major etiologic agent. Candida species vary in their epidemiology and therapy. New diagnostic, epidemiologic, and therapeutic tools have been developed and are discussed in this review. They include the use of polymerase chain reaction-based diagnostic methods, recent advances in antifungal susceptibility testing, and comparative therapeutic and prophylactic trials. As advances in prevention, diagnosis, and therapy continue, nosocomial fungal infections and the morbidity and mortality associated with them can be reduced.

Entities:  

Year:  1999        PMID: 11095808     DOI: 10.1007/s11908-999-0041-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  110 in total

1.  Risk factors for candidemia in patients with acute lymphocytic leukemia.

Authors:  H M Richet; A Andremont; C Tancrede; J L Pico; W R Jarvis
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

2.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.

Authors:  A Voss; J A Kluytmans; J G Koeleman; L Spanjaard; C M Vandenbroucke-Grauls; H A Verbrugh; M C Vos; A Y Weersink; J A Hoogkamp-Korstanje; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 3.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

Authors:  E J Anaissie; R O Darouiche; D Abi-Said; O Uzun; J Mera; L O Gentry; T Williams; D P Kontoyiannis; C L Karl; G P Bodey
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Rapid identification of Candida species in blood cultures by a clinically useful PCR method.

Authors:  J H Shin; F S Nolte; C J Morrison
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  Risk factors for candidemia in a children's hospital.

Authors:  L MacDonald; C Baker; C Chenoweth
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

8.  The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.

Authors:  J H van Burik; W Leisenring; D Myerson; R C Hackman; H M Shulman; G E Sale; R A Bowden; G B McDonald
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

9.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

10.  Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study.

Authors:  G Vreugdenhil; B J Van Dijke; J P Donnelly; I R Novakova; J M Raemaekers; M A Hoogkamp-Korstanje; M Koster; B E de Pauw
Journal:  Leuk Lymphoma       Date:  1993-11
View more
  4 in total

1.  Molecular recognition of Candida albicans (1->2)-β-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residues.

Authors:  Margaret A Johnson; Jonathan Cartmell; Nina E Weisser; Robert J Woods; David R Bundle
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

2.  Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions.

Authors:  Shiang Ning Leaw; Hsien Chang Chang; Hsiao Fang Sun; Richard Barton; Jean-Philippe Bouchara; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Validation of High Resolution Melting Analysis (HRM) of the Amplified ITS2 Region for the Detection and Identification of Yeasts from Clinical Samples: Comparison with Culture and MALDI-TOF Based Identification.

Authors:  Hans Duyvejonck; Piet Cools; Johan Decruyenaere; Kristien Roelens; Lucien Noens; Stefan Vermeulen; Geert Claeys; Ellen Decat; Els Van Mechelen; Mario Vaneechoutte
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

4.  Genetic diversity and antifungal susceptibility testing of Trichosporon asahii isolated of Intensive Care Units patients.

Authors:  Rosana Bellan de Oliveira Silva; Ana Marisa Fusco-Almeida; Marcelo Teruyuki Matsumoto; Lilian Cristiane Baeza; Tatiane Benaducci; Maria José Soares Mendes-Giannini
Journal:  Braz J Microbiol       Date:  2008-09-01       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.